Aktien Sensor

Terumo Corporation’s stock price has experienced a moderate decline, but the company’s strong market position and the promising outlook for the health care equipment and supply sector suggest a potential rebound.

Terumo Corporation has partnered with MedHub-AI to bring AI-based coronary physiology assessment technology to the Japanese market, marking a significant milestone in the industry.

Terumo Corporation has partnered with MedHub-AI to market AI-based FFR technology in Japan, aiming to improve coronary physiology assessment and drive growth in the patient temperature monitoring market.

Terumo Corporation’s Q4 2025 earnings exceeded expectations, with a 25% revenue growth, 30% increase in earnings per share, and a 15% rise in stock price, solidifying its position as a leader in the healthcare equipment industry.

Terumo Corporation has received FDA clearances for its Medis QFR 3.0 software and Carotid Stent System, marking notable achievements for the company’s divisions, Terumo Health Outcomes and Terumo Neuro.

Terumo’s WEB device celebrates 15 years of revolutionizing aneurysm treatment, but its stock price suggests a company struggling to find its footing.

The global interventional neuroradiology market is expected to experience significant growth due to increasing prevalence of neurological disorders and demand for minimally invasive treatments.

Terumo has reported strong financial results, but its cardiovascular division is facing concerns over allegations of monopolizing medical equipment repair.

Terumo Cardiovascular is facing criticism for limiting access to repair information for its medical equipment, sparking concerns about monopolies and potential impacts on patients and healthcare providers.

Terumo’s neurovascular ambitions are making waves in the industry, but the company’s stock price and financials raise questions about whether its growth momentum can be sustained.